Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Seeking Alpha longs have warned that increasing short positions in Cassava Sciences stock could result in a “short squeeze.”. For at least several days, comments on Seeking Alpha have disclosed that retail longs are receiving telephone calls from their brokers, asking if they are willing to loan their shares.

Cassava Sciences, Inc.: Recent Trading Activity Presents An Opportunity

Heron Therapeutics

As I pointed out in a previous discussion, short selling is not for the faint of heart and is probably best left to experienced traders. But there is an opportunity for investors to make money by keeping an eye on companies that could be subject to a short squeeze.

Are Herron Therapeutics, Cassava Sciences Ripe for a Short Squeeze?

Take a wild ride -- but keep your position size small, please -- as SAVA stock could return to all-time highs or plummet to new depths soon. The post Cassava Sciences Is an Exciting Roll-the-Dice Biotech Trade appeared first on InvestorPlace.

Cassava Sciences Is an Exciting Roll-the-Dice Biotech Trade

Aurinia Pharmaceuticals

Bausch Health Companies Inc

Clovis Oncology

Myovant Sciences

SPDR S&P Biotech ETF

Biotechs have been one of the worst performers for 2021 as the pandemic has wrought havoc in the sector. 2022 will likely entail a rotation out of high valuation sectors like technology into more depressed sectors like healthcare.

6 Top Biotech Ideas For 2022

Still, weighing risk against potential gains, the odds with SAVA stock may be on your side. If you are active in similar types of plays, consider it one to put on your watchlist.

Cassava Sciences Stock Is Still Risky but Has Plenty of Upside Potential

INmune Bio Inc

Both Cassava Sciences and INmune Bio have brought impressive results on neuroinflammation and neurodegeneration. I expect INmune Bio's XPro to yield impressive results in its phase 2 trials like Cassava Sciences' simufilam did.

INmune Bio, The Biotech In My Stable For After Cassava Sciences

Cassava Sciences stands to gain a good deal this year using probability methods. On a risk-adjusted basis, SAVA stock is still worth 3.7 times its present price, despite all the concerns about its downside.

Cassava Sciences Stock Is Worth Almost 4x More After Adjusting for Risk

Big 5 Sporting Goods

Bakkt Holdings

Cinedigm

CoreCivic

FuboTV

Novavax

These seven high risk stocks made wild moves in 2021, but still have the potential to rocket higher. All are full of both risk and reward.

7 High Risk Stocks That Are Worth The Volatile Vibes

It could be a make-or-break year for the clinical-stage biotech.

Where Will Cassava Sciences Be in 1 Year?

I provide and compare historical data from the GameStop and AMC short squeezes that occurred last year to Cassava Sciences. The short squeeze for Cassava Sciences has already started – as was the case for GameStop, recall that the increase in price-per-share for GameStop occurred over 12 trading days.

Cassava Sciences, Inc. - The Short Squeeze Has Started

The market is pricing in an approximately 6% chance of FDA approval for Cassava Sciences' Alzheimer's small molecule pill, Simufilam. The distribution of 147,000 Simufilam to more than 250 Alzheimer's patients in at least 16 investigator sites shows zero drug-related serious adverse events vs. 69% occurrence of ARIA with Biogen.

Cassava Sciences: Likelihood Of FDA Success Implies 11x Upside

Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Cassava Sciences (SAVA) Stock?

I do not believe that a short position in Cassava Sciences stock is rational.

Cassava Sciences, Inc. - A Rational Expectation If All Goes Well With Simufilam

Cleveland-Cliffs

Nokia

Pubmatic

Virgin Galactic

Tilray Brands

Although the meme stocks phenomenon is sagging in popularity, these seven current and/or former Reddit favorites could make another "to the moon" move or two in 2022. The post 7 of the Best Meme Stocks for 2022 to Buy Now appeared first on InvestorPlace.

7 of the Best Meme Stocks for 2022 to Buy Now

AMC Entertainment

GameStop

MicroStrategy Incorporated

Tesla

These could be some of the worst-performing and riskiest investments in 2022.

5 Stocks I'd Sell Right Now

Cue Health

Microbot Medical

Health care stocks worth knowing as the Omicron Covid-19 variant sweeps the globe.

Best Health Care Stocks To Buy Now? 3 For Your 2022 Watchlist

AUSTIN, Texas, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc., (NASDAQ: SAVA) a biotechnology company, today announced the launch of a new clinical website, called www.Rethink-ALZ.com. Rethink-ALZ.com is intended to provide access, visibility and information on Cassava Sciences' Phase 3 safety and efficacy studies of oral simufilam in people with Alzheimer's disease. Simufilam is a new oral drug candidate for the proposed treatment of mild-to-moderate Alzheimer's disease.

Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam in Alzheimer's Disease

Biotech company Cassava saw a big jump today on positive news related to its Alzheimer's disease treatment. Keep an eye on SAVA stock.

SAVA Stock Alert: What Is Going on With Red-Hot Cassava Sciences Today?

While the interim data looks fantastic, and some are pushing for early approval of the drug by the FDA, some questions remain surrounding the academic integrity of the work.

Cassava Sciences Stock: Here We Go Again

Cassava Sciences Inc (NASDAQ: SAVA) has been informed by the Neuroscience journal that there is no evidence to support claims of data manipulation in a 2005 paper authored by the Company and its scientific collaborators.  "Another science journal has cleared us of allegations," said Remi Barbier, President & CEO.

Science Journal Finds No Evidence To Data Manipulation By Cassava Sciences' In 2005 Publication

Biofrontera

Stran & Co

Are these former penny stocks on your list to buy right now or is the rally over? The post Top Penny Stocks To Buy?

Top Penny Stocks To Buy? 3 Former Stocks Under $5 To Watch Now

Cassava Sciences (SAVA) stock is getting some extra attention today from traders on social media and we've got all the details. The post SAVA Stock: The Social Media Chatter That Has Cassava Sciences Trending Today appeared first on InvestorPlace.

SAVA Stock: The Social Media Chatter That Has Cassava Sciences Trending Today

The shares of Cassava Sciences Inc (NASDAQ:SAVA) are surging before the bell, last seen up 33.6% at $49.13, as the heavily shorted stock gains popularity on social media this morning.

Cassava Stock Surges as Social Media Buzz Intensifies

The shares of Cassava Sciences, Inc. (NASDAQ: SAVA) were halted this morning. This is why it happened.

Cassava Sciences Stock (SAVA): Why The Price Surged

AUSTIN, Texas, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc., (Nasdaq: SAVA) a biotechnology company, has been informed by Neuroscience journal there is no evidence to support claims of data manipulation in a 2005 paper1 authored by the Company and its scientific collaborators. Neuroscience is a prestigious academic journal whose mission is to report “significant, new and carefully confirmed findings with full experimental details.”2

Science Journal Finds No Evidence to Support Claims of Data Manipulation in 2005 Publication

News for Cassava Sciences Inc Stock (SAVA)